Inveready leads a €3.5 Million round in Leukos Biotech, a

The principal Investigator Ruth M. Risueño will lead the development of a new class of drugs against Leukemia Stem Cells.


Madrid, 21 September 2016. 

 

Inveready has invested in LEUKOS BIOTECH, a biotechnology company founded in October 2015, by the Josep Carreras Leukemia Research Institute and by Dr. Ruth M. Risueño. The CEO is serial entrepreneur Dr. Enrique Llaudet and the Jose Carreras International Leukemia Foundation is also a shareholder.  Leukos has its headquarters in Barcelona and will develop a novel class of drugs around a newly discovered therapeutic target that selectively destroys Leukemia Stem Cells.  This new discovery opens the door to a completely new therapeutic strategy to treat Cancer Recurrence.  

 

The round will push a first candidate into clinical trials for Acute Myeloid Leukemia for patients defined as unfit, i.e., those that are 60 or over and that are not suitable for bone marrow transplant or aggressive chemotherapy. There is an unmet need for effective treatment options for these older individuals who make up 40% of all AML patients. Although bone marrow transplant can work on younger patients, there are no real alternatives for the growing unfit population.  Leukos will also develop a pipeline of follow up candidates for Leukemia Stem Cells in other types of Cancers. Dr. Ruth M. Risueño, who has extensive experience in new biological target discovery for Leukemia and is a world expert in Leukemia Stem Cells, made the original discovery of this new target.  

 

Leukos Biotech has been advised throughout by Antares Consulting: from the technology transfer process to the interim management and the business plan preparation. Antares Consulting has assisted Leukos in the identification of its CEO. The consultancy firm has also supported and accompanied the spin-off in all the fundraising process, a service provided by Antares Consulting since 2014 to research and development institutes

 

Other advisors to the transaction are: Lexcrea, RatnerPrestia and Jimenez de Parga.


Source:Antares Consulting

Copyright © 2019 Antares Consulting S.L. All rights reserved   |   Legal information and Privacy policy